Unsubscribe - AHEAD 3-45

About
- About the Study
- Participant Video Resources
Am I Eligible
- Eligibility Requirements
- Participation Requirements
Find A Location
In The News
Learn More

Menu

About
- About the Study
- Participant Video Resources
Am I Eligible
- Eligibility Requirements
- Participation Requirements
Find A Location
In The News
Learn More

Unsubscribe from the AHEAD Mailing List

Shortly after receipt, we will process your request and remove your email from our mailing list.

Name*
First Last
Email*
Email
This field is for validation purposes and should be left unchanged.

AHEAD Study Organizers

The AHEAD Study is funded by the National Institutes of Health and several philanthropic organizations, as well as Eisai, the company that makes the investigational treatment used in the study. It is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers. The study is coordinated by the University of Southern California’s Alzheimer’s Therapeutic Research Institute, Brigham and Women’s Hospital, Massachusetts General Hospital, and Harvard Medical School. Cooperative agreement number: R01AG054029 (A3), R01AG061848 (A45)

Find us on Facebook

Call 1-800-AHEAD-70 (1-800-243-2370) to see if you’re eligible to screen for the AHEAD 3-45 Study.

© 2022 AHEAD 3-45

California Privacy Rights
Privacy Policy
Terms of Use

Menu

California Privacy Rights
Privacy Policy
Terms of Use